Rankings
▼
Calendar
RNAC Q2 2019 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
RNAC
Cartesian Therapeutics, Inc.
$216M
Q2 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$13,000
Gross Profit
$13,000
100.0% margin
Operating Income
-$16M
-124884.6% margin
Net Income
-$16M
-126107.7% margin
EPS (Diluted)
$-10.96
QoQ Revenue Growth
+30.0%
Cash Flow
Operating Cash Flow
-$7M
Free Cash Flow
-$7M
Stock-Based Comp.
$1M
Balance Sheet
Total Assets
$47M
Total Liabilities
$47M
Stockholders' Equity
$56,000
Cash & Equivalents
$30M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$13,000
$0
—
Gross Profit
$13,000
$0
—
Operating Income
-$16M
-$19M
+13.5%
Net Income
-$16M
-$19M
+12.8%
← FY 2019
All Quarters
Q3 2019 →